## Medicare Detailed Written Order



## **Instructions**

- 1. Complete all fields on this Detailed Written Order.
- 2. Use the Noridian November 2017 Physician Resource Letter (Continuous Glucose Monitors) to confirm coverage criteria and medical necessity documentation requirements are met.
- 3. Fax both this order and the patient's most recent medical records that demonstrate coverage criteria are met to a DME supplier that provides the Free Style Libre 2 28-day system.

## **Patient Information**

products prescribed on this order.

Physician signature \_

Patient Name:		1	Date of Birth:					
Phone:				Email:				
Address:			(	City:		State:	Zip Code:	
Primary Insura	F	Primary Insurance Member ID:						
Secondary Insurance:				Secondary Insurance Member ID:				
along (FAX	with (dia BACK: (	e Prescription gnosis) Char (888-726-922	rt Notes.	·k Diagn	osis code (	on it and	l send us back	
Physician Information  Physician Name:				Phone:				
NPI:				FAX:				
Address:				City:		State:	Zip Code:	
			Order	Detail				
Order Date:								
E2103(Freestyle Libre 2 reader)					A4239 (Freestyle Libre 2 sensors)			
Required for new prescriptions, reader life ~3 years					28-day supply, filled monthly			
Diagnosis (I	CD10):							
O E10.9	o E11.65	o E10.65	o E11.8	o E11.9	o Othe	er:		
rescribed Num	ber of Glucose	e Tests per Day:						
Current Insu	ılin Regime	n:						
O Insulin Pump o Multiple Daily Injections-Number per Day:					o Other:			
accurate, and comp	plete to the best o	of my knowledge. I und	lerstand that any f	alsification, omi	ssion, or concealr	ment of materi	cessity information is true al fact may subject me to n the proper use of the	

It is ultimately the responsibility of the healthcare professional/persons associated with the patient's care to determine and document the appropriate diagnosis (es) and code(s) for the patient's condition. Abbott does not guarantee that the use of any information provided in this form will result in coverage or payment by any third-party payer. Each healthcare provider is ultimately responsible for verifying codes, coverage, and payment policies used to ensure that they are accurate for the services and items provided.



## **Certification of Medical Necessity Diabetes Supplies: Glucose Sensors**

Date:	-
Patient's Name: To Whom It May Concern:	Patient`s Date of Birth:
•	of Medical Necessity for the above-referenced patient upplies. The following prerequisites have been met:
<ul> <li>□ Patient has a history of severe hypoglycemia requirin</li> <li>□ Patient has experienced unawareness of hypoglycem</li> <li>□ Patient has a history of labile glucose control despite</li> <li>□ Patient has a sub-optimal A1c &gt; 7.8% (Choose target</li> <li>□ Patient has a history of nocturnal hypoglycemia.</li> <li>□ Patient demonstrates compliance to prescribed regim</li> <li>□ Patient agrees to work with their physician, nurse edu</li> </ul>	onic symptoms. optimal therapy regimes. t) despite optimal therapy regimes. nen and the willingness to attend regular medical follow-up exams.
proven to lower HbA1c resulting in improved d limit glucose excursions. Self-monitoring of blo variations.[i] Glucose sensor use may result in	e of continuous glucose sensing technology has been iabetes control, decrease of the risk of hypoglycemia and ood glucose alone does not capture daily glucose a decreased risk of hospitalizations due to treatment of ycemia, improve quality of life, and prevent or delay tight control of glycemic levels[ii][iii].
negate the need for finger stick blood glucose providing ongoing glucose values, trajectory as	sensors and adhesives. The glucose sensor does not testing but augments the management of diabetes by rrows indicating rate of glucose change, and alarms Four to six glucose sensors per month will provide sing for this patient.
I recommended that( ) be approved for cover in their diabetes care.	rage of these essential supplies as a medical necessity
Sincerely,	
Dr. () MD	
(Physician's address) 8101 Hi	nson Farm Rd, Suite 208 Alexandria VA 22306
(Physicial	n's phone): 703-746-8408

[i] Use of the Continuous glucose monitoring system inguiding therapy decisions in patients with insulin treated diabetes. Tanenberg, R, Bode, B. Mayo [ii] Tavris, D. The public health impact of the continuous glucose monitoring system. Food and Continuous glucose monitoring in type 1 Drug Administration, MD. USA. Diabetes Technology &

[iii] Weinzimmer, S, Tamborlane, W. diabetes. Yale University. Current diabetes reports 2004;4: 95-100.